MedAlliance Announces Enrollment of over 1,660 Patients in Landmark SELUTION DeNovo Study
GENEVA, Sept. 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary
Read MoreGENEVA, Sept. 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,660 patients in its ground-breaking SELUTION DeNovo coronary
Read MoreGENEVA, Sept. 6, 2023 /PRNewswire/ — The first patient has been enrolled in a UK study of large vessel de novo
Read MoreGENEVA, Aug. 16, 2023 /PRNewswire/ — MedAlliance has announced completion of patient enrollment in the SAVE Clinical Trial with the
Read MoreGENEVA, May 31, 2023 /PRNewswire/ — 12-month results from the SELUTION SFA trial have been presented at the Japan Endovascular Treatment
Read MoreGENEVA, March 15, 2023 /PRNewswire/ — MedAlliance has announced enrollment of over 1,000 patients in its ground-breaking SELUTION DeNovo coronary randomized
Read MoreGENEVA, Jan. 26, 2023 /PRNewswire/ — The first US patient has been enrolled at MedStar Washington Hospital Center in the
Read MoreGENEVA, Jan. 11, 2023 /PRNewswire/ — SELUTION SLR™, MedAlliance’s novel sirolimus-eluting balloon, has received conditional FDA Investigational Device Exemption (IDE) approval
Read MoreGENEVA, Oct. 25, 2022 /PRNewswire/ — Following our communication last week “MedAlliance to be acquired by Cordis”, MedAlliance is pleased
Read MoreGENEVA, Switzerland, Sept. 10, 2022 /PRNewswire/ — An 82-year-old Taiwanese man has become the first patient to be enrolled in
Read MoreGENEVA, Switzerland, Aug. 24, 2022 /PRNewswire/ — The first US patient has been enrolled in the FDA SELUTION4BTK (Below-the-Knee) clinical trial
Read More